{"id":"NCT00504881","sponsor":"UCB Pharma SA","briefTitle":"Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy","officialTitle":"An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (â‰¥ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2008-11","completion":"2008-12","firstPosted":"2007-07-20","resultsPosted":"2017-03-17","lastUpdate":"2018-04-03"},"enrollment":480,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Brivaracetam","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Brivaracetam","type":"EXPERIMENTAL"}],"summary":"This study will compare the safety and efficacy of Brivaracetam at flexible dose with Placebo in subjects suffering from Epilepsy.","primaryOutcome":{"measure":"Percentage of Subjects With at Least One Adverse Event During the 16-week Treatment Period","timeFrame":"Week 2 to the end of the Treatment Period (Week 16)","effectByArm":[{"arm":"Placebo","deltaMin":66.1,"sd":null},{"arm":"Brivaracetam","deltaMin":66.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":2},"locations":{"siteCount":61,"countries":["Austria","Belgium","Czechia","Germany","Hong Kong","India","Italy","Norway","Russia","Singapore","South Africa","South Korea","Sweden","Taiwan","Ukraine"]},"refs":{"pmids":["24116853","28004320","35285519","33461041"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":121},"commonTop":["Headache","Somnolence","Dizziness","Fatigue","Nausea"]}}